1. A microsatellite DNA-derived oligodeoxynucleotide attenuates lipopolysaccharide-induced acute lung injury in mice by inhibiting the HMGB1-TLR4-NF-κB signaling pathway
   Chenghua Zhang et al, 2022, Frontiers in Microbiology CrossRef
2. Efficacy and safety of Dachaihu Decoction for acute pancreatitis: Protocol for a systematic review and meta-analysis
   Xiang Xiao et al, 2023, PLOS ONE CrossRef
3. Traditional Chinese medicine for hypertrophic scars—A review of the therapeutic methods and potential effects
   Daqin Chen et al, 2022, Frontiers in Pharmacology CrossRef
4. Protective effect of pteryxin on LPS-induced acute lung injury via modulating MAPK/NF-κB pathway and NLRP3 inflammasome activation
   Tian-qi Xuan et al, 2022, Journal of Ethnopharmacology CrossRef
5. Rhei Radix et Rhizoma and its anthraquinone derivatives: Potential candidates for pancreatitis treatment
   Qi Qiu et al, 2024, Phytomedicine CrossRef
6. Emodin Ameliorates Acute Pancreatitis-Associated Lung Injury Through Inhibiting the Alveolar Macrophages Pyroptosis
   Xiajia Wu et al, 2022, Frontiers in Pharmacology CrossRef
7. Natural Chinese herbs for the prevention and treatment of acute pancreatitis: a narrative review
   Jiaqi Cui et al, 2022, Journal of Pancreatology CrossRef
8. Chrysophanol alleviates acute lung injury caused by Klebsiella pneumoniae infection by inhibiting pro‐inflammatory cytokine production
   Fei Jiang et al, 2023, Phytotherapy Research CrossRef
9. Emodin Alleviates High-Glucose-Induced Pancreatic β-Cell Pyroptosis by Inhibiting NLRP3/GSDMD Signaling
   Yiqian Xing et al, 2022, Evidence-Based Complementary and Alternative Medicine CrossRef
10. NLRP3 Inflammasome: A key contributor to the inflammation formation
    Wen-Juan Zhang et al, 2023, Food and Chemical Toxicology CrossRef
11. Combination therapy with budesonide and acetylcysteine alleviates LPS-induced acute lung injury via the miR-381/NLRP3 molecular axis
    Huimin Yu et al, 2023, PLOS ONE CrossRef
12. First‐in‐human safety, tolerability, and pharmacokinetic results of DFV890, an oral low‐molecular‐weight NLRP3 inhibitor
    Ewa Gatlik et al, 2024, Clinical and Translational Science CrossRef